The University of Southampton
University of Southampton Institutional Repository

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
Background and Objectives: We sought to identify new fusion genes with involvement of the platelet-derived growth factor receptor ß gene (PDGFRB) in three patients presenting with various subtypes of chronic myeloproliferative disorders associated with chromosomal aberrations involving chromosome bands 5q31–33.
Design and Methods: We performed 5' rapid amplification of cDNA ends (5'-RACE)-polymerase chain reaction (PCR) with RNA/cDNA derived from a patient (case #1) with a t(5;12)(q31–33;q24) and a second patient (case #2) with a complex rearrangement involving chromosomes 1, 5 and 11. A newly developed DNA-based ‘longdistance inverse PCR’ (LDI-PCR) was performed on a third patient (case #3) with a t(4;5;5)(q23;q31;q33).
Results: In cases #1 and #2, we identified mRNA fusions between GIT2 exon 12 and GPIAP1 exon 7, respectively, and PDGFRB exon 11. In case #3, LDI-PCR revealed a fusion between PRKG2 exon 5 and a truncated PDGFRB exon 12. The region encoding the catalytic domain of PDGFRß is retained in all three cases, with the partner contributing a coiled-coil domain (GPIAP1, PRKG2) or an ankyrin protein interaction motif (GIT2) that may potentially lead to dimerization and constitutive activation of the fusion proteins. Treatment with imatinib (400 mg/day) has led to sustained complete hematologic remission in all three patients.
Interpretation and Conclusions: These data provide further evidence that numerous partner genes fuse to PDGFRB in BCR-ABL negative chronic myeloproliferative disorders. Although these fusion genes occur rarely, their identification is essential in order to detect patients in whom targeted treatment with tyrosine kinase inhibitors is likely to be successful.
genetics, aged, research, female, chromosomes, drug therapy, middle aged, agents, gtpase-activating proteins, dimerization, methods, growth, treatment, transcription factors
0390-6078
163-169
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Metzgeroth, Georgia
611ec46d-9a11-4e24-ae0f-5ac19dfd0237
Haferlach, Claudia
0bf0896a-7b9c-451a-9e64-935ecdd7aa15
Schmitt-Graeff, Annette
2903ba9c-3428-4fbf-977c-3c72cbeebaa4
Fabarius, Alice
5c31b1e0-c6da-49b8-843a-5b0ca736e5a2
Hagen, Volker
046254c6-314c-43f8-b50b-7172f8936677
Prummer, Otto
9abb7650-e6d2-4e5e-8d34-6c093cd3883d
Rauh, Stefan
68a347db-deaf-4855-89be-14fbd3c781aa
Hehlmann, Rüdiger
790dac9f-3d0a-4388-b038-b5bbd07359c4
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Metzgeroth, Georgia
611ec46d-9a11-4e24-ae0f-5ac19dfd0237
Haferlach, Claudia
0bf0896a-7b9c-451a-9e64-935ecdd7aa15
Schmitt-Graeff, Annette
2903ba9c-3428-4fbf-977c-3c72cbeebaa4
Fabarius, Alice
5c31b1e0-c6da-49b8-843a-5b0ca736e5a2
Hagen, Volker
046254c6-314c-43f8-b50b-7172f8936677
Prummer, Otto
9abb7650-e6d2-4e5e-8d34-6c093cd3883d
Rauh, Stefan
68a347db-deaf-4855-89be-14fbd3c781aa
Hehlmann, Rüdiger
790dac9f-3d0a-4388-b038-b5bbd07359c4
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede

Walz, Christoph, Metzgeroth, Georgia, Haferlach, Claudia, Schmitt-Graeff, Annette, Fabarius, Alice, Hagen, Volker, Prummer, Otto, Rauh, Stefan, Hehlmann, Rüdiger, Hochhaus, Andreas, Cross, Nicholas C.P. and Reiter, Andreas (2007) Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica, 92 (2), 163-169. (doi:10.3324/haematol.10980).

Record type: Article

Abstract

Background and Objectives: We sought to identify new fusion genes with involvement of the platelet-derived growth factor receptor ß gene (PDGFRB) in three patients presenting with various subtypes of chronic myeloproliferative disorders associated with chromosomal aberrations involving chromosome bands 5q31–33.
Design and Methods: We performed 5' rapid amplification of cDNA ends (5'-RACE)-polymerase chain reaction (PCR) with RNA/cDNA derived from a patient (case #1) with a t(5;12)(q31–33;q24) and a second patient (case #2) with a complex rearrangement involving chromosomes 1, 5 and 11. A newly developed DNA-based ‘longdistance inverse PCR’ (LDI-PCR) was performed on a third patient (case #3) with a t(4;5;5)(q23;q31;q33).
Results: In cases #1 and #2, we identified mRNA fusions between GIT2 exon 12 and GPIAP1 exon 7, respectively, and PDGFRB exon 11. In case #3, LDI-PCR revealed a fusion between PRKG2 exon 5 and a truncated PDGFRB exon 12. The region encoding the catalytic domain of PDGFRß is retained in all three cases, with the partner contributing a coiled-coil domain (GPIAP1, PRKG2) or an ankyrin protein interaction motif (GIT2) that may potentially lead to dimerization and constitutive activation of the fusion proteins. Treatment with imatinib (400 mg/day) has led to sustained complete hematologic remission in all three patients.
Interpretation and Conclusions: These data provide further evidence that numerous partner genes fuse to PDGFRB in BCR-ABL negative chronic myeloproliferative disorders. Although these fusion genes occur rarely, their identification is essential in order to detect patients in whom targeted treatment with tyrosine kinase inhibitors is likely to be successful.

This record has no associated files available for download.

More information

Published date: February 2007
Keywords: genetics, aged, research, female, chromosomes, drug therapy, middle aged, agents, gtpase-activating proteins, dimerization, methods, growth, treatment, transcription factors

Identifiers

Local EPrints ID: 60393
URI: http://eprints.soton.ac.uk/id/eprint/60393
ISSN: 0390-6078
PURE UUID: 47b84246-ee48-491a-830c-16a78f38d947
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 09 Sep 2008
Last modified: 16 Mar 2024 03:23

Export record

Altmetrics

Contributors

Author: Christoph Walz
Author: Georgia Metzgeroth
Author: Claudia Haferlach
Author: Annette Schmitt-Graeff
Author: Alice Fabarius
Author: Volker Hagen
Author: Otto Prummer
Author: Stefan Rauh
Author: Rüdiger Hehlmann
Author: Andreas Hochhaus
Author: Andreas Reiter

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×